Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) released its quarterly earnings data on Tuesday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.11), Briefing.com reports. The business had revenue of $79.90 million for the quarter, compared to analyst estimates of $76.97 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.32% and a net margin of 2.78%. The company’s revenue was up 65.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.18) earnings per share.

Kiniksa Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ KNSA opened at $17.86 on Thursday. The stock has a market cap of $1.26 billion, a PE ratio of 162.38 and a beta of 0.27. Kiniksa Pharmaceuticals has a 52-week low of $10.65 and a 52-week high of $22.09. The business has a 50-day moving average price of $19.36 and a 200 day moving average price of $18.00.

Analysts Set New Price Targets

KNSA has been the subject of several analyst reports. TheStreet raised Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Thursday, February 29th. Wedbush reissued an “outperform” rating and issued a $30.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Tuesday. Finally, Evercore ISI upped their target price on Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,659 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $377,262.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 12,742 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total transaction of $273,825.58. Following the completion of the sale, the chief executive officer now directly owns 70,594 shares of the company’s stock, valued at approximately $1,517,065.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Michael R. Megna sold 9,659 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $21.45, for a total value of $207,185.55. Following the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $377,262.60. The disclosure for this sale can be found here. Insiders sold a total of 33,109 shares of company stock valued at $709,929 in the last three months. 54.23% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.